Dishman carbogen amcis Limited has announced a board meeting scheduled for March 18, 2026, to consider a significant fund raising proposal. The company has formally notified stock exchanges about this important corporate development in accordance with regulatory requirements.

Board Meeting Details

The Board of Directors will convene on Wednesday, March 18, 2026, with a specific agenda focused on fund raising activities. The meeting has been called to consider and approve a proposal for raising funds through the issuance of Non-Convertible Debentures via private placement.

Regulatory Compliance

The company has issued this intimation pursuant to Regulations 29 and 50 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Both BSE Limited and National Stock Exchange of India Limited have been formally notified about the scheduled board meeting.

Fund Raising Structure

The proposed fund raising will be executed through Non-Convertible Debentures issued via private placement. This funding mechanism is subject to obtaining necessary regulatory and statutory approvals as may be required for the transaction.

Corporate Communication

The formal intimation was signed by Shrima Dave, Company Secretary, on March 14, 2026. The notification ensures compliance with stock exchange listing requirements and keeps stakeholders informed about significant corporate decisions that may impact the company's financial structure.

Dishman Carbogen Amcis Limited has issued a detailed clarification regarding the recent credit rating downgrade by India Ratings & Research Pvt. Ltd. (IND-RA). The pharmaceutical company addressed stakeholders through a regulatory filing dated 23rd February, 2026, explaining the context behind the rating action and highlighting its improving financial metrics.

Credit Rating Downgrade Details

India Ratings recently downgraded the company's credit facilities ratings from the previous levels. The rating agency assigned new ratings taking a consolidated view of the company's operations.

The last rating exercise before this recent downgrade was undertaken by India Ratings in April 2025, when the ratings were affirmed at A+ and A1+ respectively with a stable outlook.

Improved Financial Metrics

Despite the rating downgrade, Dishman Carbogen Amcis highlighted significant improvements in its financial position. The company's net leverage ratio showed substantial improvement over the six-month period.

The company emphasized that the net leverage as on 30th September, 2025, considered for the current rating action, improved to 3.18x compared to 3.92x as on 31st March, 2025.

EBITDA Margin Performance

The company's EBITDA margins have shown consistent improvement, particularly when excluding the impact of new facilities. The consolidated EBITDA margins demonstrate a recovery trajectory.

The EBITDA margins for the group have kept improving, excluding the new French site and recently re-approved India site, as compared to the pre-EDQM observation period margins. The margins generated in FY25 and nine months ended December 31, 2025, excluding those from France and India sites, show growth compared to pre-EDQM observation margins.

Management's Position

The company stated that the recent credit rating action does not represent the improving business and financial performance of the group. Management expects to achieve EBITDA levels at pre-EDQM observation levels of 24.4% with the scale-up in business at the newly established French facility and the recently re-approved Bavla site in India, along with continuing growth at other sites.

Dishman Carbogen Amcis remains committed to maintaining transparent communication with stakeholders and has provided this clarification to ensure proper understanding of its financial position despite the rating downgrade.